



ASSH | American Society for
Surgery of the Hand

ASSH GENERAL INFORMATION & DISCLOSURES

COURSE OVERVIEW

The program will cover a variety of topics, including scaphoid reconstruction, congenital hand reconstruction, vascularized bone graft, thumb reconstruction, arthritis, flaps, tendons, Dupuytren's disease, trauma, carpal mechanics, arthroplasty, soft tissue reconstruction, nerve injuries, and more. By participating in this meeting you will have the opportunity to learn from the premier hand and upper extremity experts in field while enjoying numerous networking opportunities to strengthen your professional and personal relationships.

LEARNING OBJECTIVES

Upon completion of this course, the participant will be able to:

- Identify new treatments and techniques for unsolved hand and upper extremity surgery problems.
- Improve professional practice and patient care.
- Discuss and critique reports of clinical advances and new research findings in hand and upper extremity surgery.
- Engage with professional colleagues from the United States, Australia and others abroad.
- Evaluate a wide range of hand surgery products and technologies.

ASSH CME MISSION STATEMENT

PURPOSE - The pre-eminent mission of the ASSH is to provide state-of-the-art continuing medical education in the field of hand and upper extremity surgery. The ASSH is dedicated to fulfillment of this mission through the following means:

- To offer excellent educational programming enabling hand care professionals to provide superior medical care for the hand and upper extremity
- To enhance the dissemination of current research knowledge ensuring that hand care professionals have timely and relevant information available
- To facilitate a career-long continuum of medical education
- To foster innovation in current medical education programs
- To be a resource and model for course directors and educators involved in ASSH educational activities
- Enhance the value of care for hand and upper extremity problems by improving quality and patient safety

TARGET AUDIENCE - ASSH perpetuates the CME mission through a multidisciplinary educational audience of regional, national and international participants, which include:

Primary Audience:

- Practicing Hand Surgeons

Secondary Audience:

- Basic scientists
- All members of the health care team
- Surgeons and basic scientists in training
- Hand Therapists and Physiatrists
- Industry

CONTENT AREAS - The scope of ASSH continuing medical education foster activities in both Clinical and Non-clinical environments encompassing:

- Basic and Clinical Sciences
- Practice Management
- Medical/Legal
- Quality and Patient Safety
- Scholarship

In addition, the ASSH supports continuing medical education opportunities through joint and co-Sponsorship with other respected and recognized medical organizations, which are consistent with ACCME Essentials and Standards.

TYPE OF ACTIVITIES - ASSH cultivates traditional CME and personal interaction with member and non-member hand surgeons, hand therapists, other physicians interested in specific problems related to hand and upper extremity surgery and scientists through the following learning modalities:

- Didactic Presentations and Seminars
- Symposia and Workshops
- Teleconferences and Webcasting
- Enduring Materials
- Self-Assessment Programs

EXPECTED RESULTS - The expected results of the ASSH Educational program are to provide hand surgeons and other health care professionals with educational programs that improve their current clinical knowledge and enhance patient care by improving competence, performance, or patient outcomes.

- The goal of ASSH CME is to integrate research knowledge into clinical practice and to facilitate a career-long learning.
- Measure the outcome of modified behavior. ASSH places a strong emphasis on the assessment of results and asks “How will this educational program improve physician behavior?”
- Identify and overcome barriers to physician change. Integrate CME into health care improvement initiatives and enhance the learning and change process of physicians.

- Use evaluation tools (e.g. needs assessments, surveys, outcomes measurement, etc.) on selected courses before, during and following the program, based on the scope of the educational activity and the specific needs of the learner.
- Determination of the effectiveness of programs designed to improve the attendees' knowledge of best practices, competence, performance or patient outcomes.
- Implement changes or improvements to enhance subsequent educational activities and the overall education mission.

ACCREDITATION

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Society for Surgery of the Hand (ASSH) and the Australian Hand Surgery Society (AHSS). The ASSH is accredited by the ACCME to provide continuing medical education for physicians.

CONTINUING MEDICAL EDUCATION (CME) CREDIT HOURS

The ASSH designates this live activity for a maximum of 17.50 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NON-COMMERCIALISM

While it is rare, from time to time, presenters make reference to name-brand products, devices, pharmaceuticals/drugs, or suggest “only one way” to perform a surgical procedure. In an effort to ensure balance and avoid commercialism, the ASSH asks all presenters to use generic terminology in their presentations. Discussers are requested to provide commentary and add balance if “name-brands” or “only one way” to perform surgery are included in faculty presentations. Our goal is to avoid commercialism during continuing medical education sessions.

DISCLOSURE CRITERIA / CONFLICT OF INTEREST POLICY

Anyone who could be in a position to affect the content of a Continuing Medical Education (CME) activity must disclose all relevant financial relationships with any commercial interests. That includes, without limitation, course directors, planners, content reviewers, moderators, and instructors. For purposes of this disclosure a, “relevant financial relationship” means any amount occurring within the past 12 months that may create an actual or perceived conflict of interest. A “Commercial interest” is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

The ASSH does not view the existence of a relationship as necessarily implying bias or decreasing the value of an instructor's participation in the course. These disclosures are listed solely for the information of the listener.

Disclosures are listed as provided by the presenter. The ASSH makes no warranty, guarantee or representation as to the absolute validity or sufficiency of any information provided.

FINANCIAL DISCLOSURE – REPRESENTED BY ●

Disclosures includes any relevant financial relationships that the primary instructor or their

spouse or life partner has with a commercial interest.

FDA DISCLOSURE – REPRESENTED BY ▲

Some drugs or medical devices discussed at this course may have not been cleared by the U.S. Food & Drug Administration (FDA) or have been cleared by the FDA for specific purposes only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical device he or she wishes to use in clinical practice.

The ASSH policy provides that “off label” uses of a drug or medical device may be described in the ASSH CME activities so long as the “off label” use of the drug or medical device is also specifically disclosed (i.e., it must be disclosed that the FDA has not cleared the drug or device for the described purpose). Any drug or medical device is being used “off label” if the described use is not set forth on the product’s approval label.

◇ NO RELATIONSHIPS WITH A COMMERCIAL INTEREST TO DISCLOSE

- ◇Nicholas Adams, MD
- ◇Mark Allison, FRACS
- ◇Isam Atroshi, MD, PhD
- ◇Mark K. Baker, FRACS, FAOrthoA
- ◇Heather Baltzer, MD, MSc, FRCSC, FACS
- ◇Anthony J. Beard, FRACS
- ◇Tim Bennett, MBBS, FRACS
- ◇Jared W. Carlson, MD
- ◇A. B. Chhabra, MD
- ◇Stephen G. Coleman, FRACS
- ◇Sarah Coll, MD
- ◇Gregory Bennett Couzens, Dr
- ◇John G. Crock, MD, FRACS
- ◇Scott FM Duncan, MD, MPH, MBA
- ◇Jeff O. Ecker, BMedSc, MBBS, FRACS, FAOrthA
- ◇Ian A. Edmunds, FRACS
- ◇Mitchell Eichhorn, MD
- ◇Scott Ferris, MD
- ◇Jason Fletcher, MD
- ◇Margaret Woon Man Fok, MD
- ◇Jeffrey B. Friedrich, MD
- ◇Layan Gamage, MBChB
- ◇David Gilpin, MBBS, FRACS
- ◇Jennifer Anne Green, MD
- ◇Philip A. Griffin, FRACS
- ◇Claudia R. Gschwind, MD
- ◇Ja Hea Gu, MD
- ◇Ranjan Gupta, MD
- ◇Tim Halsey, MD
- ◇Ian C. Hargreaves, MD, FRACS

◇Isaac Harvey, BMBs, FRACS
◇Jason N. Harvey, MBBS, FRACS
◇Michael G. Hayes, MBBS, FRACS
◇Roland F. Hicks, MBBS, FRACS, FAOrthA
◇Mark Hile, MBBS, FRACS, FAOrthA
◇Jeffrey Ryan Hill, BS
◇Ajmal Ikram, FCS (Ortho)
◇Paul Max Jarrett, MBBS
◇Peter J. Jebson, MD
◇Neil F. Jones, MD
◇Thomas Joyce, PhD
◇Robin Neil Kamal, MD
◇Angus Keogh, MBBS
◇Stuart G. Kirkham, MBBS, FRACS
◇Vinay Kulkarni, MD
◇Grigorios Lamaris, MD
◇Richard D. Lawson, FRACS
◇Terry R. Light, MD
◇Shengi Lu, MD
◇Joseph Luo, MBBS
◇Avanthi Mandaleson, MD
◇James A. Masson, FRACS
◇Steven J. McCabe, MD, MSc
◇David McCombe, MBBS, MD, FRACS
◇Bryce Meads, MD
◇Matthew J. Meunier, MD
◇Suhail K. Mithani, MD
◇Amy M. Moore, MD
◇Edwin Morrison, MD
◇Wayne A. Morrison, MD
◇David T. Netscher, MD
◇Scott N. Oishi, MD
◇Daniel A. Osei, MD, MSc
◇William C. Pederson, MD, FACS
◇Tim S. Peltz, MD, PhD
◇Alexis Pereira, MD
◇Vishnu C. Potini, MD
◇Shirley Potter, FRCS(plast), PhD
◇Emma Reay, MD
◇Peter R. Rowan, MBBS, FRACS, FAOrthA
◇Sujoy Roychowdhury, MD
◇Stephen Ruff, FRACS
◇Damian P. Ryan, MD, FRACS
◇Randall Sach, FRACS
◇Andrew D. Saies, MD
◇Junko Sato, MD, PhD

◇Peter Scougall, FRCS
◇Sheena K. Sikora, MD
◇Micah K. Sinclair, MD
◇Nicholas Charles Smith, MD
◇Craig Brenton Smith, MD
◇Karen Smith, FRACS
◇Garret Sobol, MD
◇Sadhishaan Sreedharan, MD
◇David Stabler, MBBS, FRACS
◇Peter J. Stern, MD
◇David A. Stewart, FRACS
◇Jai Sungaran, FRACS
◇Stephen Tham, FRACS
◇Tom Thorvaldson, FRACS
◇Michael A. Tonkin, MD
◇Yuan-Kun Tu, MD
◇Carley B. Vuillermin, MBBS, FRACS
◇Jennifer F. Waljee, MD
◇John Hakon Williksen, MD
◇Jennifer Moriatis Wolf, MD
◇Robert W. Wysocki, MD

FINANCIAL/FDA DISCLOSURES

●Marie A. Badalamente, PhD

- Royalty fees received from: Biospecifics Technologies Corp.
- Consulting fees received from: Actelion Pharmaceuticals, Endo Pharmaceuticals

●Anthony C. Berger, FRACS

- Speakers Bureau: Actelion Pharmaceuticals

●Randip R. Bindra, FRCS, MCh Orth

- Royalty fees received from: Integra Lifesciences
- Consulting fees received from: Integra Lifesciences, Acumed
- Speakers Bureau: Integra Lifesciences
- Fees for non-CME services received directly from a Commercial Interest or its Agent: Actelion Pharmaceuticals

●Carlton M. Clinkscales, MD

- Consulting fees received from: Stryker, MicroAire, Endo Medical, Osteomed, Pinnacol Assurance
- Ownership Interest (stocks, stock options, or other ownership interest, excluding diversified mutual funds) in: Stryker

●Edward Diao, MD

- Receipt of Intellectual Property Rights/Patent Holder with: Surgical Drape

- Speakers Bureau: Stryker
- **Scott G. Edwards, MD**
 - Speakers Bureau: Medartis
 - Contracted Research: Medartis
- **Peter J. Evans, MD, PhD**
 - Royalty fees received from: Biomet, Hely-Webber
 - Consulting fees received from: Biomet, AxoGen, Acumed
 - Ownership Interest (stocks, stock options, or other ownership interest, excluding diversified mutual funds) in: Nutek Orthopaedics
- **Thomas J. Fischer, MD**
 - Consulting fees received from: Synthes
- **Graham J. Gumley, FRACS**
 - Consulting fees received from: Austofix, Double Engine Medical
- **Ian W. Incoll, FRACS**
 - Consulting fees received from: Acumed
- **Jonathan E. Isaacs, MD**
 - Speakers Bureau: Axogen, Inc
 - Contracted Research: AxoGen, Inc.
- **Sanjeev Kakar, MD**
 - Consulting fees received from: Arthrex, Skeletal Dynamics, AM Surgical
 - Contracted Research: Arthrex
- **Scott H. Kozin, MD**
 - Consulting fees received from: Checkpoint Surgical
- **Amy L. Ladd, MD**
 - Royalty fees received from: Orthohelix
 - Consulting fees received from: Pacira
 - Ownership Interest (stocks, stock options, or other ownership interest, excluding diversified mutual funds) in: Illuminoss, Articulinx
- **Lisa L. Lattanza, MD**
 - Consulting fees received from: Conventus
 - Speakers Bureau: Acumed, Tornier
 - Ownership Interest (stocks, stock options, or other ownership interest, excluding diversified mutual funds) in: Mylad
- **Fraser J. Leversedge, MD**
 - Royalty fees received from: Orthohelix Surgical Designs, Tornier

- Consulting fees received from: Stryker Orthopaedics, AxoGen, Bioventus
- Contracted Research: AxoGen, Bioventus

● **L. Scott Levin, MD, FACS**

- Royalty fees received from: Mavrek, Inc.
- Receipt of Intellectual Property Rights/Patent Holder with: Sternal Talon
- Contracted Research: Axogen, Inc.

● **▲ Steven L. Moran, MD**

- Royalty fees received from: Integra
- Consulting fees received from: Integra
- Ownership Interest (stocks, stock options, or other ownership interest, excluding diversified mutual funds) in: Axogen
- ▲ Presentation may include discussion of the use of hemi-joint replacement in the MCP and PIP joints, an "off-label" or other non-FDA approved use of a device manufactured by Integra.

● **David B. O'Gorman, MSc, PhD**

- Contracted Research: BetaCat Pharma

● **Mark M. Perko, MD**

- Contracted Research: Device Technologies, Arthrex

● **Gary M. Pess, MD**

- Royalty fees received from: Biomet
- Speakers Bureau: Endo Pharmaceuticals, Inc

● **Raymond B. Raven, MD, MBA**

- Royalty fees received from: Osteomed, Advanced Orthopaedic Solutions
- Receipt of Intellectual Property Rights/Patent Holder with: Osteomed, Advanced Orthopaedic Solutions
- Consulting fees received from: Osteomed
- Ownership Interest (stocks, stock options, or other ownership interest, excluding diversified mutual funds) in: McGinley Orthopaedic Innovations

● **Marc J. Richard, MD**

- Consulting fees received from: Acumed
- Speakers Bureau: Acumed
- Contracted Research: Acumed

● **Melvin P. Rosenwasser, MD**

- Royalty fees received from: Biomet
- Consulting fees received from: Stryker, DJO Global, Biomet

● **Mark Ross, FRACS**

- Royalty fees received from: Integra Life Sciences, Lockdown
- Receipt of Intellectual Property Rights/Patent Holder with: Integra Life Sciences
- Lockdown
- Consulting fees received from: Integra Life Sciences, Lima
- Speakers Bureau: Depuy, Integra Life Sciences, LMT, Lima
- Contracted Research: Integra Life Sciences, Lima, Medartis

●**David S. Ruch, MD**

- Royalty fees received from: Acumed, Zimmer
- Speakers Bureau: Acumed

●**Bauback Safa, MD, MBA**

- Speakers Bureau: Axogen, Inc.
- Contracted Research: Axogen, Inc.

●**Michael J. Sandow, BMBS, FRACS, FAOrthA**

- Receipt of Intellectual Property Rights/Patent Holder with: 3D Animation Technology
- Contracted Research: Wright Medical
- Ownership Interest (stocks, stock options, or other ownership interest, excluding diversified mutual funds) in: True Life Anatomy

●**William H. Seitz, Jr., MD**

- Consulting fees received from: Stryker Orthopaedics, Kapp Surgical Instruments, Materialise

●**Philip G. Slattery, FRACS**

- Consulting fees received from: Actelion Pharmaceuticals

●**T. Greg Sommerkamp, MD**

- Consulting fees received from: Pacira Pharmaceuticals, Inc

●**Dean G. Sotereanos, MD**

- Consulting fees received from: Arthrex, Axogen, Smith & Nephew

●**Allan Wang, FRACS, PhD**

- Ownership Interest (stocks, stock options, or other ownership interest, excluding diversified mutual funds) in: Orthocell

●**Arnold-Peter C. Weiss, MD**

- Royalty fees received from: DePuy, Medartis, Extremity Medical
- Receipt of Intellectual Property Rights/Patent Holder with: IllumniOss Medical, DePuy
- Ownership Interest (stocks, stock options, or other ownership interest, excluding diversified mutual funds) in: IllumniOss Medical

●**Jeffrey Yao, MD**

- Royalty fees received from: Arthrex
- Receipt of Intellectual Property Rights/Patent Holder with: Arthrex, Elevate Braces
- Consulting fees received from: Arthrex, Smith and Nephew Endoscopy, BME
- Speakers Bureau: Arthrex, Smith and Nephew Endoscopy
- Ownership Interest (stocks, stock options, or other ownership interest, excluding diversified mutual funds) in: Elevate Braces, McGinley Orthopedics, 3D Systems

++

ASSH CONTACT INFORMATION

Phone: 1-312-880-1900

Email: meetings@assh.org

Web: www.assh.org